Background: The patients undergoing cancer treatment are experiencing a wide range of toxicity. This study is on cancer patients diagnosed with stage II non-small cell lung cancer (NSCLC).
Aim and Objective: The primary objective was to study and grade the various toxicities of paclitaxel (PTX) cisplatin (CDDP) combination, using the World Health Organizations toxicity grading scale. The secondary objective was to assess patient response to PTX-CDDP regimen.
Materials and Methods: This study is done at a tertiary care center using a prospective observational study design. CDDP-PTX regimen is followed in the department of radiotherapy for 49 patients for 1 year. For doing the statistical analysis, the data collected were entered and analyzed using a Microsoft Excel worksheet. The toxicity grading was analyzed using SPSS software.
Results: Total patients participated are 49 out of which only four were females, and 45 were male patients. The age range of patients was between 56 and 88 years. The treatment regimen followed in this study had several toxicities. Toxicity developed in the patients belongs to various categories, mainly gastrointestinal, hematological, and dermatological toxicities. Response evaluation criteria analyze the clinical response in solid tumors (RECIST criteria).
Conclusions: This study helps us to understand the wide range of adverse drug reactions; the cancer patient may go through during chemotherapy. When compared with the earlier studies, the incidence of diarrhea and renal toxicity is less due to adequate preventive measures.
Key words: Cancer Treatment; Drug Toxicity Profile; Lung Cancer; National Securities Clearing Corporation Ltd.; Paclitaxel-Cisplatin Regimen, Stage II Non-small Cell Lung Cancer; The World Health Organizations Toxicity Criteria